Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 9/20 | 0.35 |
| ▸ | AKT1 | P31749 | 9/20 | 0.35 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | HIPK1 | Q86Z02 | 3/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.33 |
| ▸ | HIPK3 | Q9H422 | 3/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.33 |
| ▸ | CLK1 | P49759 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904772 | 0.94 | ROCK2 (0.42) | ROCK2ROCK1AKT2AKT1CLK2 | |
| SCHEMBL12095412 | 0.92 | TACR3 (0.38) | AKT2AKT1PDE2ATACR3 | |
| SCHEMBL14118751 | 0.89 | TACR3 (0.34) | AKT2AKT1PDE2ATACR3 | |
| SCHEMBL12095444 | 0.87 | AKT1 (0.35) | AKT2AKT1PDE2ATACR3 | |
| SCHEMBL14118537 | 0.86 | PDE2A (0.34) | AKT2AKT1PDE2ATACR3 | |
| SCHEMBL14118957 | 0.86 | TACR3 (0.41) | AKT1PDE2ATACR3 | |
| SCHEMBL14119220 | 0.85 | AKT1 (0.34) | AKT2AKT1CLK2HIPK1HIPK2 | |
| SCHEMBL14119305 | 0.85 | AKT1 (0.40) | ROCK2ROCK1AKT2AKT1CLK2 | |
| SCHEMBL14119065 | 0.85 | HDAC1 (0.33) | AKT2AKT1MAPK1PDE2ATACR3 | |
| SCHEMBL12095518 | 0.83 | AKT1 (0.34) | AKT2AKT1PDE2ATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | ROCK2 557/4885ROCK1 688/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.